Cell therapy development is changing healthcare. Due to the increasing availability of cell therapy treatments, thousands of patients worldwide have new hope for a positive disease outcome. As we scale up to treat more patients, there will be an increase in the challenges related to the vein-to-vein workflow.

While current approaches can manage the existing volume of cell therapy shipments, scaling these treatments up and out will increase pressure on existing cryogenic logistics networks. Considering and addressing these challenges early in a therapy’s development could help reduce the risk of future supply chain disruptions.

Here, we consider the challenges and risks associated with the cryogenic supply chain for cell therapies and provide considerations for mitigation strategies.

Not yet a member of BioProcess Online? Register today.

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: